Our discussion of biosimilars in this article will center on developed-market GMP biosimilars. In the European market alone, biosimilars already are a multibillion-dollar business, and one that is rapidly growing.
Ronald A. Rader
Ronald A. Rader, senior director of technical research at BioPlan Associates, Inc., has 30+ years of experience as a biotechnology, pharmaceutical, and chemical information specialist/analyst. He was editor/publisher of the Antiviral Agents Bulletin, Federal Bio-Technology Transfer Directory, and BIOPHARMA: Biopharmaceutical Products in the U.S. Market.
